<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel H Sterman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Leslie A Litzky, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Larry R Kaiser, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rogerio C Lilenbaum, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Vallières, MD, FRCSC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 11, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Malignant mesothelioma is a rare and insidious neoplasm with a poor prognosis. It arises from mesothelial surfaces of the pleural cavity, peritoneal cavity, tunica vaginalis, or pericardium. Malignant pleural mesothelioma (MPM) is the most common type and can be difficult to treat because most patients have advanced disease at presentation.</p><p>The clinical presentation, evaluation, staging, and prognosis of MPM will be reviewed here. Epidemiology and treatment of pleural mesothelioma, as well as issues related to peritoneal mesothelioma are covered elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4625.html" rel="external">"Epidemiology of malignant pleural mesothelioma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4608.html" rel="external">"Pathology of malignant pleural mesothelioma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4626.html" rel="external">"Initial management of malignant pleural mesothelioma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/82913.html" rel="external">"Malignant peritoneal mesothelioma: Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H3769944552"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>The 2021 WHO Classification of Tumors of the Pleura proposes significant changes to the 2015 WHO Classification. Among other changes, well-differentiated papillary mesothelioma now is called well-differentiated papillary mesothelial tumor based on findings that these tumors behave in a relatively indolent fashion. The term "malignant" has been dropped as a prefix from localized and diffuse mesothelioma and mesothelioma in situ has been added to the new classification because these lesions can be recognized with certain biomarkers such as the loss of <em>BRCA1</em>-associated protein 1 (<em>BAP1</em>). Epithelioid, biphasic, and sarcomatoid subtypes remain the same, but cytologic and stromal features are more formally incorporated based on their prognostic significance. Several other changes also are proposed along with the recognition that the most frequently altered genes in diffuse pleural mesothelioma include <em>BAP1</em>, cyclin-dependent kinase inhibitor 2A (<em>CDKN2A)</em>, <em>NF2</em>, <em>TP53</em>, <em>SETD2</em>, and <em>SETDB1</em> [<a href="#rid1">1-3</a>].</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The vast majority of MPM occur in patients age 60 years and older, typically presenting decades after an exposure to asbestos with gradually worsening, nonspecific pulmonary symptoms. The epidemiology of MPM is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4625.html" rel="external">"Epidemiology of malignant pleural mesothelioma"</a>.)</p><p>Symptoms, signs, and findings on imaging are discussed in the sections below.</p><p class="headingAnchor" id="H16617531"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Most patients with MPM present with the gradual onset of nonspecific symptoms such as chest pain, dyspnea, cough, hoarseness, night sweats, or dysphagia, which occur in the setting of extensive intrathoracic disease. Distant metastatic spread is less common but rarely can involve the bone, liver, or central nervous system (CNS). Systemic symptoms such as fatigue and weight loss may also be present, particularly in patients with advanced disease. Symptoms may be present for months or longer prior to diagnosis.</p><p>In very rare instances, patients with mesothelioma will present with acute symptoms of local invasion of vital structures. For example, involvement of the brachial plexus or compression of the spinal cord may lead to focal neurologic deficits. Growth through the diaphragm may lead to bowel obstruction, resulting in abdominal pain, distension, and vomiting. Impingement on the superior vena cava may cause symptoms of head fullness or facial swelling. Cardiac involvement may lead to arrhythmias or heart failure. Other rare presentations of MPM include paraneoplastic syndromes [<a href="#rid4">4-8</a>], although these are generally seen in the context of advanced disease that presented earlier with more typical symptoms. Reported paraneoplastic conditions include disseminated intravascular coagulation, migratory thrombophlebitis, thrombocytosis, hypoglycemia, various neurologic disorders, renal disease, and hypercalcemia.</p><p class="headingAnchor" id="H1344586869"><span class="h2">Physical exam findings</span><span class="headingEndMark"> — </span>Common physical findings at the time of diagnosis generally are due to a pleural effusion, which is almost always present, and include unilateral dullness to percussion at the lung base, decreased air movement on the side of involvement, and asymmetric chest wall expansion during respiration. Palpable chest wall masses, as well as tumor nodules in previous incision or thoracentesis puncture sites, and scoliosis toward the side of the malignancy may be seen with advanced disease.</p><p class="headingAnchor" id="H16617524"><span class="h2">Findings on imaging</span><span class="headingEndMark"> — </span>Chest imaging is generally done as part of the initial symptom evaluation. Typically, chest radiograph (CXR) is the initial exam, although a chest computed tomography is often pursued subsequently given limited sensitivity and specificity with CXR. Common radiographic findings for patients with pleural mesothelioma include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A unilateral pleural abnormality with a large, unilateral pleural effusion  (<a class="graphic graphic_diagnosticimage graphicRef52053" href="/z/d/graphic/52053.html" rel="external">image 1A</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>A pleural mass or rind or diffuse pleural thickening in the absence of a pleural effusion  (<a class="graphic graphic_diagnosticimage graphicRef52053 graphicRef70651" href="/z/d/graphic/52053.html" rel="external">image 1A-B</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural plaques and/or calcifications.</p><p class="bulletIndent1"><span class="glyph">●</span>Ipsilateral mediastinal shift due to encasement of lung by a thick rind of tumor and relative ipsilateral lung volume loss.</p><p></p><p>Other radiographic features concerning for malignancy, although less specific for mesothelioma, include unilateral loss of lung volume, loss of normal fat planes, and gross extension of a mass into mediastinal fat [<a href="#rid9">9</a>]. Only 20 percent of patients with pleural mesothelioma have radiographic signs of asbestosis (such as bibasilar interstitial fibrosis).</p><p>For patients who are imaged by positron emission tomography, increased uptake of fluorodeoxyglucose (FDG) is observed. (See <a class="local">'Advanced imaging'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Clinical suspicion for MPM may arise in the setting of respiratory symptoms in the context of pleural thickening or an effusion on chest imaging and a history of asbestos exposure. Although these features may raise the suspicion of MPM, a biopsy is necessary to confirm the diagnosis [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H727191605"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Initial evaluation of patients with suspected MPM includes contrast-enhanced computed tomography of the chest to identify pleural abnormalities and extent of disease, thoracentesis of any existing pleural effusion, and closed pleural biopsy. Further imaging for diagnosed cases of MPM, including positron emission tomography, is discussed below. (See <a class="local">'Advanced imaging'</a> below.)</p><p>However, frequently this initial approach does not provide sufficient tissue to definitively establish a diagnosis of MPM and, specifically, to differentiate it from adenocarcinoma. In such instances, surgical intervention via video-assisted thoracoscopic (VATS) biopsy or open thoracotomy should be pursued. Additionally, we evaluate with concurrent bronchoscopy at the time of surgery, as endobronchial lesions are typically not seen in mesothelioma, and their presence argues against this diagnosis. This also allows for the performance of endobronchial ultrasound (EBUS)-guided biopsies of mediastinal pleural lesions, tumor masses in the subcarinal space, and mediastinal and hilar lymph nodes ipsilateral and contralateral to the primary process, which provides staging information if MPM is diagnosed. (See <a class="local">'Surgical staging'</a> below.)</p><p>The difficulties in establishing a diagnosis of mesothelioma are illustrated by a study of 188 consecutive patients evaluated between 1973 and 1990 [<a href="#rid11">11</a>]. Thoracentesis and pleural fluid cytology yielded a diagnosis in 26 percent of cases, and thoracentesis plus closed pleural biopsy was diagnostic in 39 percent of cases. By contrast, VATS was diagnostic in 98 percent of cases. (See  <a class="medical medical_review" href="/z/d/html/4388.html" rel="external">"Medical thoracoscopy (pleuroscopy): Equipment, procedure, and complications"</a>.)</p><p>Approximately 10 percent of patients who undergo an invasive diagnostic procedure for mesothelioma seed the biopsy site with tumor cells and later develop a chest wall recurrence. The role of prophylactic radiation therapy to prevent this complication is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4626.html" rel="external">"Initial management of malignant pleural mesothelioma"</a>.)</p><p class="headingAnchor" id="H1474714371"><span class="h2">Tissue diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of pleural mesothelioma is established by morphologic and immunohistochemical features of a cytologic or surgical specimen [<a href="#rid10">10</a>].</p><p>Most malignant mesothelioma appear as one of three histologic subtypes: epithelioid, sarcomatoid, or biphasic (mixed). Within each subgroup, a broad range of morphologic features may be present or absent, making morphology alone insufficient to establish the diagnosis in most cases. However, based on morphology and the degree of differentiation of the tumor, specific immunohistochemical markers are chosen to evaluate the specimen further. Because no single immunohistochemical marker exhibits high sensitivity or specificity, the International Mesothelioma Interest Group recommends using a panel of at least two immunoreactive and two nonimmunoreactive markers to establish the diagnosis of mesothelioma [<a href="#rid12">12</a>]. Similarly, according to several European expert groups, standard staining procedures are insufficient in approximately 10 percent of cases, justifying the use of specific markers, including <em>BAP1</em> and cyclin-dependent kinase inhibitor 2A (<em>CDKN2A</em> [<em>p16</em>]), for the separation of atypical mesothelial proliferation from MPM [<a href="#rid13">13</a>]. The immunohistochemistry as well as other features of pathology are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4608.html" rel="external">"Pathology of malignant pleural mesothelioma", section on 'Histology'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of MPM includes both benign and malignant processes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign conditions</strong> – Inflammatory reactions, such as chronic organized empyema, can often mimic the dense parietal and visceral pleural thickening along with a large pleural effusion that is characteristic of mesothelioma. However, on pathologic examination, stromal invasion is present in the case of MPM but absent with benign disease. (See  <a class="medical medical_review" href="/z/d/html/4608.html" rel="external">"Pathology of malignant pleural mesothelioma", section on 'Histology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignant conditions</strong> – Other malignant conditions can present in a similar clinical and radiographic pattern as mesothelioma and may share similar morphologic characteristics under microscopy. For example, certain sarcomas can present in similar fashion and infiltrate like sarcomatoid mesotheliomas and may even appear histologically similar to sarcomatoid mesothelioma. As further examples, pleural metastases of peripheral lung adenocarcinomas, as well as metastases to the pleura from a number of solid tumors (including but not limited to the lung, breast, stomach, kidney, ovary, thymus, and prostate), may grossly and histologically resemble epithelioid mesothelioma. Immunohistochemical patterns of staining can distinguish mesothelioma from these entities. (See  <a class="medical medical_review" href="/z/d/html/4608.html" rel="external">"Pathology of malignant pleural mesothelioma", section on 'Immunohistochemistry'</a>.)</p><p></p><p class="headingAnchor" id="H16615464"><span class="h1">STAGING AND PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>While virtually all patients with MPM will receive chemotherapy, one goal of staging is to identify patients who may benefit from surgical resection as well. Staging and pretreatment evaluation also establishes baseline disease burden and organ function before beginning chemotherapy [<a href="#rid14">14</a>].</p><p>Clinical staging with imaging is the initial staging evaluation for patients with MPM. However, clinical staging often underestimates the extent of disease, and pathologic staging provides a more reliable assessment of whether or not the patient is a candidate for surgical resection.  (<a class="graphic graphic_figure graphicRef87269" href="/z/d/graphic/87269.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H16615788"><span class="h2">Staging systems</span><span class="headingEndMark"> — </span>The most widely used staging system is the tumor, node, metastasis (TNM) staging system that has been adopted by the International Union Against Cancer (UICC), the American Joint Committee on Cancer (AJCC), and the European Society for Radiotherapy and Oncology (ESTRO), among others. Both the seventh edition  (<a class="graphic graphic_table graphicRef81665" href="/z/d/graphic/81665.html" rel="external">table 1</a>) and the eighth edition  (<a class="graphic graphic_table graphicRef111000" href="/z/d/graphic/111000.html" rel="external">table 2</a>), which went into effect on January 1, 2018, are shown [<a href="#rid15">15</a>]. In both of these editions, stage I and II disease have pleural involvement and may involve diaphragmatic muscle or pulmonary parenchyma, but lack lymph node involvement or distant metastases. In the seventh edition, stage III mesothelioma includes locally advanced disease, including cases with regional lymph node involvement; and stage IV disease includes those with locally advanced unresectable disease, contralateral lymph node involvement, supraclavicular lymph node involvement, or distant metastases. In the eighth edition of the TNM staging system, however, stage IV disease includes only those with distant metastases; other tumors previously considered stage IV, including locally advanced unresectable disease, will be considered as a subset of stage III disease.</p><p>To develop the eighth edition of the TNM system, the International Association for the Study of Lung Cancer and the International Mesothelioma Interest Group used a database with information on 3101 patients with mesothelioma diagnosed in 15 centers between 1995 and 2009 [<a href="#rid14">14</a>]. The information in this database was correlated with various prognostic factors (see <a class="local">'Prognostic factors'</a> below). A second database including 3519 patients diagnosed between 2000 and 2013 in 29 centers worldwide was developed to acquire more detailed TNM information to further refine the staging system.</p><p>Other staging systems have been developed and are used at some centers. As an example, the Brigham staging system is a modification of the older Butchart system [<a href="#rid16">16</a>]. Involvement of hilar, ipsilateral, and midline mediastinal lymph nodes categorizes a patient as stage II. In addition, the presence of positive surgical margins also qualifies for classification as stage II. Invasion of chest wall, mediastinum, heart, esophagus, or contralateral structures upstages a patient to stage III, as does extrapleural nodal involvement.</p><p>A major limitation of all of the staging systems is the difficulty in assessing the extent of disease prior to treatment. In a database study including 1056 cases in which both clinical and pathologic staging were available, clinical staging was unreliable, with approximately 80 percent of clinical stage I patients and 70 percent of stage II patients being upstaged following pathologic evaluation based upon surgery  (<a class="graphic graphic_figure graphicRef87269" href="/z/d/graphic/87269.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H16615949"><span class="h2">Staging evaluation</span><span class="headingEndMark"> — </span>The initial staging evaluation for MPM is through imaging, followed by surgical staging for those in whom surgical resection is being considered. (See  <a class="medical medical_review" href="/z/d/html/4626.html" rel="external">"Initial management of malignant pleural mesothelioma", section on 'Patient selection and rationale for surgery'</a>.)</p><p class="headingAnchor" id="H3519107013"><span class="h3">Advanced imaging</span><span class="headingEndMark"> — </span>For diagnosed cases of pleural mesothelioma, we obtain integrated positron emission tomography with computed tomography (PET-CT) as part of the staging assessment [<a href="#rid10">10</a>]. The use of PET aids in assessment of the mediastinal lymph nodes, for which CT has only limited sensitivity [<a href="#rid17">17,18</a>]. For patients in whom resection is being considered, additional imaging with magnetic resonance imaging (MRI) may help define the local extent of disease. MRI is particularly useful for those in whom there is a concern based on previous imaging for involvement of the brachiocephalic vessels, chest wall, central mediastinal structures, or diaphragm. For example, in the latter instance, coronal MRI images may identify extension of pleural mesothelioma through the diaphragm into the peritoneal cavity, which would preclude surgical intervention  (<a class="graphic graphic_diagnosticimage graphicRef66436 graphicRef78690" href="/z/d/graphic/66436.html" rel="external">image 2A-B</a>) [<a href="#rid19">19</a>].</p><p>Several series have suggested that PET-CT imaging is the most reliable imaging modality for initial assessment, particularly in determining whether a tumor is resectable [<a href="#rid20">20-22</a>]. For example, in one series, 42 consecutive patients with potentially resectable disease based upon CT were assessed with PET-CT [<a href="#rid20">20</a>]. In 12 cases (29 percent), patients were reclassified as inoperable based upon the presence of a T4 lesion or distant metastasis (29 and 14 percent, respectively). In another series of 54 patients who underwent imaging followed by surgical staging, PET-CT was more accurate than CT or PET alone or MRI in assessing stage and extent of disease [<a href="#rid21">21</a>].</p><p>Early studies suggest that staging determined by volumetric CT, in which tumor volumes are calculated semiautomatically from CT measurements, may correlate with overall survival. In a study of 164 patients, volume correlated with pathologic TNM staging and overall survival, best defined by three groups with average volumes of 91, 245, and 511 cm<sup>3</sup>, associated with median overall survival of 37, 18, and 8 months, respectively [<a href="#rid23">23</a>]. Further study is indicated before incorporation into routine practice.</p><p>In an attempt to define standardized guidelines for the radiologic assessment of MPM, a multidisciplinary meeting of mesothelioma experts was held in March 2017, from which has arisen a consensus statement. Recommendations include CT with contrast optimized to visualize the tumor and 1-mm axial images acquired in soft-tissue kernel to allow for multiplanar reformats and volumetric estimation; MRI with contrast and diffusion-weighted imaging, if available; and serial fluorodeoxyglucose (FDG) PET-CT for response evaluation. Standardization of imaging protocols across centers of expertise to allow for pooling of data for future research was also recommended [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H16616377"><span class="h3">Surgical staging</span><span class="headingEndMark"> — </span>For patients in whom imaging suggests resectable disease, we pursue extended surgical staging prior to definitive surgery. Specifically, this includes mediastinoscopy or endobronchial ultrasound (EBUS)-mediated staging of mediastinal lymph nodes. It typically also includes laparoscopy with peritoneal lavage to detect subdiaphragmatic involvement, which is most useful when there is concern for invasion of the diaphragm. Patient selection for surgical intervention is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4626.html" rel="external">"Initial management of malignant pleural mesothelioma", section on 'Patient selection and rationale for surgery'</a>.)</p><p>Extended surgical staging has prognostic utility, but also may guide management [<a href="#rid25">25,26</a>]. For example, in a series of 118 consecutive patients, surgical staging with laparoscopy with peritoneal lavage followed by mediastinoscopy allowed 14 percent of patients to avoid an inappropriate intervention [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H16617048"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>For patients with MPM, we obtain routine prechemotherapy laboratory tests, including a complete blood count with platelets, liver function tests, and serum alkaline phosphatase. We also obtain lactate dehydrogenase for its prognostic utility [<a href="#rid27">27-29</a>] (see <a class="local">'Prognostic scoring systems'</a> below). For patients in whom surgical resection is being considered, we obtain pulmonary function tests prior to surgery to determine whether residual lung function after surgery will be sufficient.</p><p>Several biomarkers are selectively elevated in patients with mesothelioma. Some UpToDate experts follow soluble mesothelin-related peptides for patients on treatment, although this is not uniform. This and other biomarkers are discussed below. (See <a class="local">'Biomarkers under investigation'</a> below.)</p><p class="headingAnchor" id="H2276513023"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis of patients with MPM is poor, with overall survival being on the order of 9 to 17 months after diagnosis [<a href="#rid30">30-32</a>]. Few patients are cured [<a href="#rid33">33,34</a>]. The majority of affected patients die from local extension and respiratory failure. In some cases, tumor extension below the diaphragm may result in death from small bowel obstruction. Patients may also die from arrhythmias, heart failure, or stroke caused by tumor invasion of the heart or pericardium.</p><p class="headingAnchor" id="H1220479852"><span class="h2">Prognostic factors</span><span class="headingEndMark"> — </span>Stage and histology are the strongest prognostic factors among patients with mesothelioma, with sarcomatoid and biphasic histologic subtypes having worse outcomes compared with epithelioid mesothelioma  (<a class="graphic graphic_figure graphicRef111002" href="/z/d/graphic/111002.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef111003" href="/z/d/graphic/111003.html" rel="external">figure 3</a>). The pure epithelioid variant is associated with the best prognosis especially if the disease can be completely resected. Other poor prognostic features include poor performance status, age &gt;75 years, elevated lactate dehydrogenase (LDH), and hematologic abnormalities [<a href="#rid27">27,35,36</a>]. These factors are included in scoring systems discussed below. (See <a class="local">'Prognostic scoring systems'</a> below.)</p><p>Information from a database of approximately 3100 patients, developed to refine the tumor, node, metastasis (TNM) staging system, suggests the prognostic importance of histology and stage. In this database, median survivals for those with epithelial, biphasic, and sarcomatoid histology were 19, 13, and 8 months  (<a class="graphic graphic_figure graphicRef87271" href="/z/d/graphic/87271.html" rel="external">figure 4</a>) [<a href="#rid14">14</a>]. Based upon surgical staging when available (and clinical staging for those without surgical staging)  (<a class="graphic graphic_table graphicRef81665" href="/z/d/graphic/81665.html" rel="external">table 1</a>), patients with stage I, II, III, and IV disease had median survivals of 20, 19, 16, and 11 months, respectively  (<a class="graphic graphic_figure graphicRef87270" href="/z/d/graphic/87270.html" rel="external">figure 5</a>).</p><p class="headingAnchor" id="H2824375189"><span class="h2">Prognostic scoring systems</span><span class="headingEndMark"> — </span>Prognostic scoring systems that incorporate both the extent of disease as well as systemic factors have been developed by the European Organisation for Research and Treatment of Cancer (EORTC) and the Cancer and Leukemia Group B (CALGB). While these scoring systems were developed prior to the use of <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">pemetrexed</a>, which has subsequently become a standard treatment option for mesothelioma, subsequent study has supported the prognostic value of the EORTC index [<a href="#rid37">37</a>].</p><p>The EORTC reviewed data from 204 adults with MPM who were entered into five consecutive phase II trials over nine years [<a href="#rid35">35</a>]. Patients with all stages of disease were permitted. When five factors were taken into consideration (poor performance status, high white blood cell [WBC] count, male sex, sarcomatous subtype, and the certainty of the diagnosis), a good and bad prognostic group could be discerned, with one-year survival rates of 40 and 12 percent, respectively  (<a class="graphic graphic_table graphicRef74894" href="/z/d/graphic/74894.html" rel="external">table 3</a>). Median survival from the date of study entry was 8.4 months. The prognostic significance of the EORTC index has subsequently been confirmed in a multivariate analysis of a phase III trial assessing <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="10087" href="/z/d/drug information/10087.html" rel="external">raltitrexed</a> [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma", section on 'Single-agent chemotherapy'</a>.)</p><p>Similarly, the CALGB evaluated the impact of clinical characteristics on the survival of 337 patients with malignant mesothelioma (of any stage and arising from any anatomic site) who were enrolled in phase II treatment studies [<a href="#rid27">27</a>]. In multivariate analysis, pleural (as compared with peritoneal or pericardial) involvement, serum LDH greater than 500 international units/L, poor performance status, chest pain, platelet count over 400,000/microL, nonepithelial histology, and age older than 75 years jointly predicted poor survival. Six distinct prognostic subgroups were generated with median survival times ranging from 1.4 to 13.9 months  (<a class="graphic graphic_table graphicRef73700" href="/z/d/graphic/73700.html" rel="external">table 4</a>). The median survival overall was seven months. This prognostic schema was subsequently validated in an American phase II trial evaluating the investigational agent ranpirnase and in an independent European data set [<a href="#rid28">28,29</a>].</p><p>A novel Mesothelioma Weighted Grading Scheme (MWGS) has been proposed that assigns weighted scores from 0 to 10 based on age, histologic type, necrosis, mitotic count, nuclear atypia, and <em>BAP1</em> expression [<a href="#rid38">38</a>]. In 369 consecutive patients with diffuse pleural mesothelioma median survival was 17.1, 10.1, and 4.1 months for low, intermediate, and high grades based on their weighted scores. A progressive increase in score correlated with worsening overall survival.</p><p>The small number of mesothelioma patients enrolled in clinical trials and the heterogeneity of study populations has limited the identification of molecular biomarkers for prognosis. New molecular technologies, such as gene expression profiling, may eventually classify patients into distinct prognostic subgroups [<a href="#rid39">39,40</a>].</p><p class="headingAnchor" id="H2423291832"><span class="h1">BIOMARKERS UNDER INVESTIGATION</span><span class="headingEndMark"> — </span>Several biomarkers are selectively elevated in patients with mesothelioma. However, further study and validation is required before these are recommended for diagnosis of mesothelioma. Some UpToDate experts follow serial measurements of soluble mesothelin-related peptides (SMRPs) as an adjunct to imaging in monitoring treatment response in those found to have elevations at the time of diagnosis of mesothelioma.</p><p>SMRPs are found in serum or pleural fluid and are believed to be peptide fragments of mesothelin, a glycoprotein present on normal mesothelial cells and overexpressed on mesothelioma cells [<a href="#rid41">41,42</a>]. However, SMRPs are not elevated in sarcomatoid lesions, have limited sensitivity in other histologic subtypes, and are also elevated in other malignancies, and therefore are of limited diagnostic utility. A meta-analysis of 16 diagnostic studies found that the sensitivity of serum SMRPs ranged from 19 to 68 percent, depending upon the specific criterion for positivity [<a href="#rid43">43</a>]. In patients with stage I or II disease, the sensitivity was only 32 percent when a specificity criterion of 95 percent was used. SMRPs have also been measured in pleural fluid [<a href="#rid44">44-46</a>], with one retrospective study suggesting sensitivity of 67 percent and specificity of 98 percent [<a href="#rid45">45</a>].</p><p>Other biomarkers of interest include fibulin-3, osteopontin, and the secreted growth factor amphiregulin (AREG) [<a href="#rid47">47-52</a>], although more study is needed before routine clinical use. High cytosolic AREG expression may be of prognostic value and potentially useful as a stratification factor in future clinical trials. Utilizing data collected during the Mesothelioma Avastin <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">Cisplatin</a> <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">Pemetrexed</a> Study (MAPS/NCT00651456), MST1/hippo kinase expression loss was predictive of poor prognosis [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H1972014728"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112231.html" rel="external">"Society guideline links: Diagnosis and management of lung cancer"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/129230.html" rel="external">"Society guideline links: Pleural mesothelioma"</a>.)</p><p class="headingAnchor" id="H108030975"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83443.html" rel="external">"Patient education: Pleural mesothelioma (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/83057.html" rel="external">"Patient education: Asbestos exposure (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Malignant pleural mesothelioma (MPM) is a rare insidious neoplasm that typically presents with advanced disease. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients with MPM present with the gradual onset of nonspecific symptoms such as chest pain, dyspnea, cough, hoarseness, or dysphagia, which occur in the setting of extensive intrathoracic disease. (See <a class="local">'Symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chest imaging typically shows unilateral pleural thickening and pleural effusion. (See <a class="local">'Findings on imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cigarette smoking is not a risk factor for the development of MPM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Initial evaluation of patients with suspected MPM includes computed tomography (CT) of the chest with contrast, thoracentesis of any existing pleural effusion, and closed pleural biopsy. However, if insufficient tissue is acquired to make a diagnosis, surgical intervention via video-assisted thoracoscopic biopsy or open thoracotomy should be pursued. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of pleural mesothelioma is established by morphologic and immunohistochemical features of a cytologic or surgical specimen. (See <a class="local">'Tissue diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/4608.html" rel="external">"Pathology of malignant pleural mesothelioma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of MPM includes benign processes such as inflammatory reactions, as well as malignant processes, including metastases from other solid tumors. Evidence of stromal invasion on biopsy distinguishes mesothelioma from benign etiologies, while immunohistochemistry can distinguish mesothelioma from other malignancies. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging evaluation</strong> – For diagnosed cases of pleural mesothelioma, we obtain integrated positron emission tomography (PET) with CT (PET-CT) as the initial staging assessment. For patients in whom imaging suggests resectable disease, we pursue extended surgical staging prior to definitive surgery. Specifically, this includes laparoscopy with peritoneal lavage to detect subdiaphragmatic involvement, followed by mediastinoscopy. (See <a class="local">'Staging evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The prognosis of patients with MPM is poor, with overall survival being on the order of 9 to 17 months after diagnosis. Few patients are cured. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biomarkers under investigation</strong> – Several biomarkers are selectively elevated in patients with mesothelioma, including soluble mesothelin-related peptides, fibulin-3, and osteopontin, although they are not routinely used in the diagnosis of mesothelioma. (See <a class="local">'Biomarkers under investigation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. J Thorac Oncol 2022; 17:608.</a></li><li><a class="nounderline abstract_t">Dacic S. Pleural mesothelioma classification-update and challenges. Mod Pathol 2022; 35:51.</a></li><li><a class="nounderline abstract_t">Beasley MB, Galateau-Salle F, Dacic S. Pleural mesothelioma classification update. Virchows Arch 2021; 478:59.</a></li><li><a class="nounderline abstract_t">Socola F, Loaiza-Bonilla A, Bustinza-Linares E, et al. Recurrent thrombotic thrombocytopenic purpura-like syndrome as a paraneoplastic phenomenon in malignant peritoneal mesothelioma: a case report and review of the literature. Case Rep Oncol Med 2012; 2012:619348.</a></li><li><a class="nounderline abstract_t">Wong SF, Newland L, John T, White SC. Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report. J Med Case Rep 2012; 6:261.</a></li><li><a class="nounderline abstract_t">Li JY, Yong TY, Kuss BJ, et al. Malignant pleural mesothelioma with associated minimal change disease and acute renal failure. Ren Fail 2010; 32:1012.</a></li><li><a class="nounderline abstract_t">Bech C, Sørensen JB. Polyneuropathy in a patient with malignant pleural mesothelioma: a paraneoplastic syndrome. J Thorac Oncol 2008; 3:1359.</a></li><li><a class="nounderline abstract_t">Tanriverdi O, Meydan N, Barutca S, et al. Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a female patient with pleural malignant mesothelioma. Jpn J Clin Oncol 2013; 43:563.</a></li><li><a class="nounderline abstract_t">Patz EF Jr, Shaffer K, Piwnica-Worms DR, et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol 1992; 159:961.</a></li><li><a class="nounderline abstract_t">Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36:1343.</a></li><li><a class="nounderline abstract_t">Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 1993; 72:394.</a></li><li><a class="nounderline abstract_t">Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med 2018; 142:89.</a></li><li><a class="nounderline abstract_t">Scherpereel A, Opitz I, Berghmans T, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 2012; 7:1631.</a></li><li class="breakAll">American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th ed, Amin MB, Edge SB, Greene FL, et al (Eds), Springer, Chicago 2017.</li><li><a class="nounderline abstract_t">Richards WG. Recent advances in mesothelioma staging. Semin Thorac Cardiovasc Surg 2009; 21:105.</a></li><li><a class="nounderline abstract_t">Heelan RT, Rusch VW, Begg CB, et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 1999; 172:1039.</a></li><li><a class="nounderline abstract_t">Marom EM, Erasmus JJ, Pass HI, Patz EF Jr. The role of imaging in malignant pleural mesothelioma. Semin Oncol 2002; 29:26.</a></li><li><a class="nounderline abstract_t">Miller WT Jr, Gefter WB, Miller WT Sr. Asbestos-related chest diseases: plain radiographic findings. Semin Roentgenol 1992; 27:102.</a></li><li><a class="nounderline abstract_t">Sørensen JB, Ravn J, Loft A, et al. Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy. Eur J Cardiothorac Surg 2008; 34:1090.</a></li><li><a class="nounderline abstract_t">Plathow C, Staab A, Schmaehl A, et al. Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results. Invest Radiol 2008; 43:737.</a></li><li><a class="nounderline abstract_t">Wilcox BE, Subramaniam RM, Peller PJ, et al. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer 2009; 10:244.</a></li><li><a class="nounderline abstract_t">Rusch VW, Gill R, Mitchell A, et al. A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma. Ann Thorac Surg 2016; 102:1059.</a></li><li><a class="nounderline abstract_t">Gill RR, Tsao AS, Kindler HL, et al. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol 2019; 14:1718.</a></li><li><a class="nounderline abstract_t">Rice DC, Erasmus JJ, Stevens CW, et al. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg 2005; 80:1988.</a></li><li><a class="nounderline abstract_t">Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: who benefits? Chest 1995; 107:345S.</a></li><li><a class="nounderline abstract_t">Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113:723.</a></li><li><a class="nounderline abstract_t">Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000; 55:731.</a></li><li><a class="nounderline abstract_t">Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002; 20:274.</a></li><li><a class="nounderline abstract_t">Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636.</a></li><li><a class="nounderline abstract_t">Ahamad A, Stevens CW, Smythe WR, et al. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 2003; 9:476.</a></li><li><a class="nounderline abstract_t">Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27:3007.</a></li><li><a class="nounderline abstract_t">Yang CF, Adil SM, Anderson KL, et al. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer. Eur J Cardiothorac Surg 2016; 49:1607.</a></li><li><a class="nounderline abstract_t">Musk AW, Olsen N, Alfonso H, et al. Predicting survival in malignant mesothelioma. Eur Respir J 2011; 38:1420.</a></li><li><a class="nounderline abstract_t">Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16:145.</a></li><li><a class="nounderline abstract_t">Fennell DA, Parmar A, Shamash J, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 2005; 23:184.</a></li><li><a class="nounderline abstract_t">Bottomley A, Coens C, Efficace F, et al. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 2007; 25:5770.</a></li><li><a class="nounderline abstract_t">Fuchs TL, Chou A, Aksoy Y, et al. A Critical Assessment of Current Grading Schemes for Diffuse Pleural Mesothelioma With a Proposal for a Novel Mesothelioma Weighted Grading Scheme (MWGS). Am J Surg Pathol 2022; 46:774.</a></li><li><a class="nounderline abstract_t">Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003; 95:598.</a></li><li><a class="nounderline abstract_t">Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 2004; 10:849.</a></li><li><a class="nounderline abstract_t">Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992; 16:259.</a></li><li><a class="nounderline abstract_t">Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003; 16:192.</a></li><li><a class="nounderline abstract_t">Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012; 30:1541.</a></li><li><a class="nounderline abstract_t">Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173:1155.</a></li><li><a class="nounderline abstract_t">Creaney J, Yeoman D, Naumoff LK, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007; 62:569.</a></li><li><a class="nounderline abstract_t">Davies HE, Sadler RS, Bielsa S, et al. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 2009; 180:437.</a></li><li><a class="nounderline abstract_t">Pass HI, Levin SM, Harbut MR, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012; 367:1417.</a></li><li><a class="nounderline abstract_t">Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353:1564.</a></li><li><a class="nounderline abstract_t">Hiraki A, Aoe K, Ueoka H. Asbestos exposure and serum osteopontin. N Engl J Med 2006; 354:304.</a></li><li><a class="nounderline abstract_t">Muñoz A, Barceló R, López-Vivanco G. Malignant mesothelioma. N Engl J Med 2006; 354:305.</a></li><li><a class="nounderline abstract_t">Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007; 13:2928.</a></li><li><a class="nounderline abstract_t">Maille E, Levallet J, Dubois F, et al. A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial. Int J Cancer 2022; 150:1889.</a></li><li><a class="nounderline abstract_t">Maille E, Brosseau S, Hanoux V, et al. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. Br J Cancer 2019; 120:387.</a></li></ol></div><div id="topicVersionRevision">Topic 4627 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35026477" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34465883" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pleural mesothelioma classification-update and challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33475835" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pleural mesothelioma classification update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23082261" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Recurrent thrombotic thrombocytopenic purpura-like syndrome as a paraneoplastic phenomenon in malignant peritoneal mesothelioma: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22937937" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20722572" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Malignant pleural mesothelioma with associated minimal change disease and acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18978574" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Polyneuropathy in a patient with malignant pleural mesothelioma: a paraneoplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23475537" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a female patient with pleural malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1414807" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29346042" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8319171" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28686500" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32451346" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23070243" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Initial analysis of the international association for the study of lung cancer mesothelioma database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23070243" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Initial analysis of the international association for the study of lung cancer mesothelioma database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19822281" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recent advances in mesothelioma staging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10587144" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11836666" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The role of imaging in malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1609299" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Asbestos-related chest diseases: plain radiographic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18799318" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18791416" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19632941" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27596916" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31470129" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16305830" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Extended surgical staging for potentially resectable malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7781416" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mesothelioma and radical multimodality therapy: who benefits?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9515850" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10950889" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773179" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860938" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14740977" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19364962" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26719403" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21737558" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Predicting survival in malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9440736" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625372" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18089874" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34907994" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A Critical Assessment of Current Grading Schemes for Diffuse Pleural Mesothelioma With a Proposal for a Novel Mesothelioma Weighted Grading Scheme (MWGS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12697852" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Using gene expression ratios to predict outcome among patients with mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14871960" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Gene expression profiles predict survival and progression of pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1599018" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12640097" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Value of mesothelin immunostaining in the diagnosis of mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412141" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16456138" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17356060" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19299498" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23050525" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16221779" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16422024" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Asbestos exposure and serum osteopontin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16422026" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17504993" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35262190" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30739911" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
